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ABSTRACT
OBJECTIVE: To estimate the direct costs of schizophrenia for the public sector.
METHODS: A study was carried out in the state of São Paulo, Brazil, during 1998.
Data from the medical literature and governmental research bodies were gathered for
estimating the total number of schizophrenia patients covered by the Brazilian Unified
Health System. A decision tree was built based on an estimated distribution of patients
under different types of psychiatric care. Medical charts from public hospitals and
outpatient services were used to estimate the resources used over a one-year period.
Direct costs were calculated by attributing monetary values for each resource used.
RESULTS: Of all patients, 81.5% were covered by the public sector and distributed
as follows: 6.0% in psychiatric hospital admissions, 23.0% in outpatient care, and
71.0% without regular treatment. The total direct cost of schizophrenia was
US$191,781,327 (2.2% of the total health care expenditure in the state). Of this total,
11.0% was spent on outpatient care and 79.2% went for inpatient care.
CONCLUSIONS: Most schizophrenia patients in the state of São Paulo receive no
regular treatment. The study findings point out to the importance of investing in
research aimed at improving the resource allocation for the treatment of mental disorders
in Brazil.
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RESUMO
OBJETIVO: Estimar o custo direto da esquizofrenia para o setor público.
MÉTODOS: O estudo foi realizado no Estado de São Paulo, no ano de 1998.
Utilizaram-se dados da literatura e de institutos governamentais de pesquisa para
estimar o número total de pacientes com esquizofrenia no Estado sob cobertura do
Sistema Único de Saúde. Foi construída uma árvore de decisão mostrando a
distribuição desses pacientes quanto ao nível de tratamento. Por meio de pesquisa em
prontuários de alguns hospitais públicos e serviços ambulatoriais, documentou-se a
utilização de recursos por esses pacientes no período de um ano. Foram atribuídos
valores em Reais para esses recursos a fim de se calcular o custo direto total médico-
hospitalar.
RESULTADOS: Do total de pacientes, 81,5% estão sob cobertura do SUS e
encontram-se assim distribuídos: 6,0% internados, 23,0% em tratamento ambulatorial
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INTRODUCTION
Although schizophrenia affects only 1.0% of the adult
world population, the care for this disorder consumes
approximately 1.6% to 2.6% of the total health costs
of Western developed countries.11 The largest share
of these costs (70% to 80%) is due to psychiatric
hospital admissions, while outpatient care is left with
less than 10%.2-4 Schizophrenia also causes a high
degree of disability. lt was ranked 8th among illnesses
bearing the heaviest global burden due to disability
among the 15-44-year-old population.12 Despite its
importance, there are few estimates of the cost of this
disorder in developing countries.
By 1998, approximately 75.0% of the Brazilian
population was covered by the Sistema Único de
Saúde (SUS - National Unified Health System). The
financial deficit of this program in the country in-
creases the importance of obtaining the first cost
estimates of proposed treatments. This should assist
government health officials in resource allocation
and decision making.
The aim of the present study was to estimate the di-
rect costs of schizophrenia for the public sector.
METHODS
The study was carried out in the State of São Paulo
during 1998 which has a population estimated in 38
million and is the major industrial and economic
powerhouse of the Brazilian economy.
In a first step, it was estimated the number of schizo-
phrenia covered by SUS. From a review of local1,6 and
international5,9,10 prevalence studies of schizophre-
nia, it is believed that the prevalence rate range be-
tween 0.5% and 1.0% of the adult population in São
Paulo. According to the last Brazilian census, about
177,000 patients were estimated for the highest preva-
lence (0.7%). In order to estimate the percentage of
these patients covered by the public sector, national
data was reviewed and the attribution rate based on
20 experts interviewed was obtained.
In a second step, it was built a decision tree that
showed the distribution of these patients as to the
form of care (psychiatric hospital admissions and
outpatient care). Thus, it was estimated the number
of patients without regular care (this group also in-
cluded patients without any kind of care). To esti-
mate the number of hospitalized patients and the
number of those under outpatient care in the begin-
ning of the year, electronic government data were
used (Datasus). The results of a prospective cohort
study of schizophrenia carried out in São Paulo7,*
were used as a reference to estimate the distribution
of all hospitalized patients in the State São Paulo
after six months of follow-up. One-hundred and
thirty five patients from a psychiatric clinic in the
State of São Paulo were followed up during 1998 to
assess the distribution of the outpatient group after
six months. The number of patients without regular
care was calculated by the difference between the
total number of patients and the number of patients
being treated.
In the third step, it was recorded medical and hospital
resources (medical appointments, maintenance and/or
urgent medication, dental care, diagnostic tests re-
quested, emergency visits, resources used with associ-
ated illnesses) used by a sample of these patients in the
different care settings. By screening public medical
services records, the resource used was recorded and
considered as the standard measure for São Paulo. A
total of 28 patients studied was hospitalized in a psy-
chiatric hospital, 14 patients in a psychiatric ward of a
general hospital, 36 patients in a psychiatric outpa-
tient clinic and 42 day hospital patients. In order to
e 71,0% sem tratamento regular. O custo direto total da esquizofrenia foi de R$222
milhões (US$191,781,327) (2,2% do total de gastos em saúde do Estado), sendo 11%
destinados ao tratamento ambulatorial e 79,2% às internações psiquiátricas.
CONCLUSÕES: A maior parte dos pacientes com esquizofrenia no Estado está sem
tratamento regular. Os achados apontam para a necessidade de se investir em pesquisas
que possam orientar uma melhor alocação de recursos no tratamento dos transtornos
mentais no País.
DESCRITORES: Gastos em saúde. Custos diretos de serviços. Esquizofrenia.
*Menezes PR. The outcome of schizophrenia and related psychoses after hospitalization: a prospective study in São Paulo, Brazil
[dissertation]. Londres: Universidade de Londres; 1995.
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estimate the resources used by the group of patients
without regular care, the attribution rate was obtained
based on 20 experts interviewed.
In the fourth step, it was assigned values in Real (the
local currency, converted into US dollars using the
mean 1998 exchange rate*) for the resources used, so
as to calculate the direct medical cost of schizophre-
nia for the public sector. To determine the cost of
medications, the values adopted were government
stipulated prices or those of the Brazilian price index
for pharmaceutical products. In order to estimate rela-
tive costs of professional and administrative services,
budgets from psychiatric hospitals and outpatient
services were also carefully identified.
The final step consisted of carrying out a sensitivity
analysis to estimate the minimum and maximum costs
of schizophrenia for the State of São Paulo, accord-
ing to a lesser or greater utilization of the available
health care system.
RESULTS
Taking into account the 0.7% prevalence in the adult
population there are estimated 177,163 schizophre-
nia patients in the State of São Paulo. It was esti-
mated that 81.5% (144,400) of these patients were
covered by the public sector in 1998. The Figure shows
the distribution of patients covered by the public sec-
tor throughout 1998.
At the beginning of the year, 6.0% of the patients
were hospitalized (3.7% were new hospital admis-
sions and 2.3% long-stay patients). It was considered
that the long-stay patients would remain hospital-
ized all year around. New hospitalized pa-
tients showed the following distribution at
the beginning of the second semester: 30.5%
remained hospitalized, 47.0% were in out-
patient care, 21.0% were without care and
1.5% was deceased. At the beginning of the
year, 23.0% were in outpatient care and six
months later only 2.7% were hospitalized and
8.0% had dropped treatment. Most of them
(89.2%) went on outpatient care throughout
the year. The remaining 71.0% were without
regular care and after six months only 2.7%
of them were hospitalized and 1.0% in out-
patient care.
New hospital admissions (short-stay patients)
consumed more resources than long-stay pa-
tients. For the former group the most frequent
procedure was psychiatrist visits, while for the
latter it was therapy sessions. Laboratory tests and elec-
troencephalograms were little requested. For new hos-
pital admissions, only one out of 10 patients made
these tests within a month period. For long-stay pa-
tients these tests were not requested.
The most frequent procedure for outpatient care was
psychiatrist visits with an average of 0.5 appoint-
ments/month/patient. Except for social worker visits
(average of 0.01/month/patient) no other professional
services were requested.
It was assumed that patients without regular care have
mainly used resources in two ways: a) emergency care
in emergency clinics; and b) the use of over-the-coun-
ter medication (irregular care). According to the ques-
tionnaire handed out to specialists, it was estimated
that a patient without care attends, on average, to
0.45 emergency visits per month.
The psychiatrists who were inquired said that on av-
erage 33.0% of the patients without care use over-
the-counter medications. In the absence of any fur-
*In 1998, US$ 1 was worth R$1,16.
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Figure - Distribution of patients covered by the public sector. State of São
Table 1 - Estimated one-month medical resource utilization
per patient in psychiatric admissions. State of São Paulo,
Brazil, 1998.
Resource New admission Long-stay
patient
Number of psychiatrist visits 16.3 5.0
General clinical evaluation 3.8 0.7
Number of social worker visits 3.5 2.4
Number of psychologist visits 3.5 1.7
Occupational therapist visits 1.7 1.0
Dentist visits 1.6 0.1
Number of group therapy sessions 1.9 5.4
Number of complete blood count 0.1 -
Fasting plasma glucose 0.1 -
Electroencephalogram 0.1 -
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ther source of data, it was assumed that these patients
use about one-third of the medication consumed by
patients undergoing outpatient care.
The direct cost of schizophrenia in the different care
modalities is showed in Table 2. Roughly 80.0% of
the estimated cost was for psychiatric hospital ad-
missions (48.7% for new hospital admissions and
30.5% for long-stay patients) and only 11.0% was
attributed to outpatient care.
The cost of medications and its percentage were cal-
culated separately (Table 3). About 7.2% of the total
direct cost referred to the use of medications. In the
outpatient sector this represented 42.0% of its costs
and in the hospital sector only 1.5%.
The sensitivity analysis for the cost of schizophrenia
is showed in Table 4. The scenario 1 represents a situa-
tion in the health care network with the largest utiliza-
tion possible and scenario 2, the least utilization. The
estimated total direct costs for the care of schizophre-
nia varied from US$146,241,268 to US$237,191,306
in 1998.
DISCUSSION
There are only few prevalence studies on schizophre-
nia in Brazil, which have some methodological limi-
tations as to the size of the sample studied. Therefore
it was not possible to precisely determine this dis-
ease prevalence in the local population. Despite these
limitations, the study findings are in accordance with
the international literature, which support the cur-
rent idea that schizophrenia has a similar prevalence
with slight variations throughout the world.
The data available was not sufficient to precisely es-
timate the number of schizophrenia patients covered
by the public sector. Brazil has a segmented health
system consisting of the Unified Health System (con-
trolled by the public sector), the private sector (health
care plans) and the fee-for-service sector. Trying to
determine the clientele of each of these sectors is a
difficult task, because some people use the three sys-
tems indiscriminately. Based on an extensive national
survey on this subject and on the attribution rates
given by the psychiatrists inquired, this present study
estimates that a minimum of 73.0% and a maximum
of 90.0% of schizophrenia patients are covered by
the public sector.
The percentage of schizophrenia patients who are not
being treated (patients without regular care) was esti-
mated to be 71.0%, an alarming proportion. How-
ever, it is important to note that this figure includes
those patients receiving irregular care, such as spo-
radic visits to emergency clinics. Moreover, those who
probably never received care in their lifetime were
included in this group. In a widespread, door-to-door,
epidemiological study9 carried out in India in 1986,
it was verified that one-third of all individuals with
schizophrenia had never received psychiatric care,
even though this type of medical care was available
Table 2 - Direct cost (US$) of schizophrenia for the public
sector. State of São Paulo, 1998.
Variable Costs (US$) %
New admissions 93,344,189 48.7
Outpatient treatment 21,061,550 11.0
Long stay patients 58,537,379 30.5
Without treatment 18,838,209 9.8
Total 191,781,327 100.0
Table 3 - Cost (US$) of medication in the different treatment modalities and its proportion to the total direct cost of schizophrenia.
State of São Paulo, 1998.
Variable Medication (US$) Total (US$) Medication/total
New admissions 1,666,862 93,344,189 1.8%
Outpatient treatment 8,851,924 21,061,550 42.0%
Long stay patients 752,090 58,537,379 1.3%
Without treatment 2,546,524 18,838,209 13.5%
Total 13,817,400 191,781,327 7.2%
Table 4 - The total direct medical cost for schizophrenia for larger and smaller utilization scenarios of the health care network.
State of São Paulo, 1998.
Variable Scenario 1 Scenario 2
% Costs US$ % Costs US$
New admissions 4.9 123,617,980 2.5 63,070,398
Outpatient treatment 27.4 25,090,716 18.4 16,849,240
Long stay patients 2.8 71,262,896 1.8 45,811,862
Without treatment 64.9 17,219,714 77.3 20,509,768
Total 100.0 237,191,306 100.0 146,241,268
Scenario 1: Larger utilization of the health care network
Scenario 2: Smaller of the health care network
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to the population. Therefore, one can infer that pa-
tients without care at any given moment are over a
third. In Brazil, there is no epidemiological data about
this group. In Holland, based on epidemiological sur-
veys and medical records, it was estimated that in
1990, 25% schizophrenia patients had never been
diagnosed or treated.3 According to this study, if pa-
tients without care at any given time were included,
even though they had undergone some kind of care
previously, this figure would increase to 64.0%, ap-
proaching the estimated results for the State of São
Paulo (71.0%).
The use of estimated resources for the group of pa-
tients without care should be looked at carefully, in-
asmuch as the only source of information was the
rates provided by the group of psychiatrists inquired
(attribution rate). Although frequently used in sur-
veys on the economics of health care, the attribution
rates should, preferably speaking, be compared to data
in other surveys. In the present study, this compari-
son was not possible due to the lack of available data
on the group of patients without care in Brazil.
Another reason for underestimating the total direct
costs is that the following costs were not included in
the study: transportation of patients and their rela-
tives; interning patients under custody (judicial in-
sane asylums); suicide attempts followed, or not, by
death; criminal and judicial surveys and training pro-
grams; infrastructure and others. However, because of
the methodological difficulties in measuring these
costs, they are rarely accounted for in relevant sur-
veys or they are used very conservatively, which does
not preclude a comparison between the results ob-
tained and those from existing literature.
As such, the direct costs of schizophrenia estimated
in the study correspond to 2.2% of the total health
care expenditures for 1998 in the State of São Paulo.
For the estimated direct cost for larger and lesser uti-
lization scenarios of the health care network, this share
will range from 1.7% to 2.7%. These figures are in
agreement with those obtained in studies12 carried
out in developed countries, which indicate that the
direct cost of schizophrenia is equivalent to 1.6% to
2.6% of the total health care expenditures. More re-
cently, a study15 showed that in Taiwan health care
expenditures for schizophrenia account for around
1.2% of total.
However, health care expenditures of developed coun-
tries correspond to 7.0% to 12.0% of their gross do-
mestic product11 (GDP), a far greater rate than 3.1%
for the State of São Paulo, which confirms the view
that insufficient resources are allocated for health care
in the Brazilian scenario.
Outpatient care, which has been associated with a
better quality of life for patients at a lower cost, re-
ceives only about 11.0% of the resources allocated
to treating schizophrenia meanwhile psychiatric hos-
pital admissions consume almost 80.0% of the budget.
Studies12,15 of the overall costs of schizophrenia in
other countries confirm the high share of the total
that is attributable to inpatient care. In the UK, a
study13 showed that illness relapse is a major factor
for high hospitalization rates and costs. Medication
non-adherence seems to have a consistent associa-
tion with greater resource use, and is a key factor in
the use of inpatient and external services.14
It is very likely that many severe cases of schizophre-
nia in Brazil have remained untreated for a one-year
period, being reasonable to conclude that these
patients do not receive adequate psychiatric care.
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